News >

Surufatinib Improves PFS in Advanced Pancreatic Neuroendocrine Tumors

Gina Columbus @ginacolumbusonc
Published: Wednesday, Jan 22, 2020

Christian Hogg, chief executive officer of Chi-Med

Christian Hogg

Surufatinib improved progression-free survival (PFS) compared with placebo in patients with low- or intermediate-grade advanced pancreatic neuroendocrine tumors (pNETs) for whom there is no effective therapy, according to a preplanned interim analysis of the phase III SANET-p trial (NCT02589821) that was completed by an independent data monitoring committee (IDMC).1

The median PFS was 21.2 months (95% CI, 15.9-24.8) and 13.4 months (95% CI, 7.6-19.3), respectively. Regarding safety, the most common grade ≥3 treatment-related adverse events included hypertension (33%), proteinuria (12%), hyperuricemia (10%), hypertriglyceridemia (6%), diarrhea (6%), and increased alanine aminotransferase (5%).


  1. Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early [news release]: London, UK. Hutchison China MediTech Limited. Published January 20, 2020. Accessed January 21, 2020.
  2. Xu J, Li J, Bai C, et al. Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, single-arm, open-label, phase Ib/II trial. Clin Cancer Res. 2019;25(12):3486-3494. doi: 10.1158/1078-0432.CCR-18-2994.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication